TrianglePembrolizumab (NCT04865887)
Pembrolizumab trial for Cervical Cancer (NCT04865887). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged 18+ with locally advanced or metastatic cervical cancer that progressed on, or could not tolerate, a prior treatment line. Prior PD-1 or PD-L1 pathway immunotherapy is excluded.
The idea: combine pembrolizumab, which releases an immune brake, with lenvatinib, which blocks blood-vessel growth signals. Participants receive pembrolizumab 200 milligrams intravenously every three weeks and lenvatinib 20 milligrams orally daily. Archived or fresh tumor tissue is required. Researchers measure responses and safety.
This phase 2 study plans 35 patients. Georgetown leads it; three US sites are recruiting, including Washington.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.